Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company BioBlast Pharma Ltd.
DescriptionMitochondrial protein replacement
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationUrea cycle disorder (UCD)
Indication DetailsTreat ornithine transcarbamylase deficiency (OTCD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today